Publications by authors named "Carmen de Lucas Collantes"

Article Synopsis
  • - X-linked hypophosphatemia (XLH) is a rare disorder caused by high levels of FGF23, leading to phosphate loss and decreased vitamin D production, while burosumab is a treatment that helps restore phosphate levels by inhibiting FGF23.
  • - This post-authorization safety study (PASS) monitors the long-term safety of burosumab in children and adolescents aged 1-17 years, with this first interim analysis focusing on the initial safety outcomes based on registry data.
  • - The analysis involved 67 participants, with 37.3% reporting at least one adverse event, primarily musculoskeletal issues; however, there were no serious adverse events or treatment withdrawals, indicating that the safety profile of
View Article and Find Full Text PDF
Article Synopsis
  • Autosomal dominant loss-of-function variants in CTLA-4 cause immune system issues like autoimmunity and immunodeficiency, known as IDAIL, which show variability in symptoms due to genetic modifiers.* -
  • The study identifies a patient with a pathogenic CTLA-4 variant and a rare DECTIN-1 variant that affects DECTIN-1's function, leading to reduced immune regulation.* -
  • DECTIN-1 is shown to enhance the differentiation of regulatory T cells and plays a critical role as a modifier that influences the severity of immune defects caused by CTLA-4 haploinsufficiency.*
View Article and Find Full Text PDF

Purpose: To determine whether hypercapnia is associated with risk of hospital readmission related to anorexia nervosa (AN) in children and adolescents.

Methods: We performed a prospective study of patients ≤ 18 years old admitted due to AN decompensation from November 2018 to October 2019. Both subtypes of AN, restricting subtype (AN-R) and binge-eating/purging subtype (AN-BP), were included.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked hypophosphatemia (XLH) is a rare genetic disorder that causes phosphate wasting in the kidneys and is linked to increased levels of the hormone FGF23; its rarity can lead to delayed diagnosis, worsening patient outcomes.
  • The International XLH Registry was launched in 2017 to gather data on XLH patients of all ages, with an interim analysis reporting on 579 participants as of March 2021, highlighting a longer diagnosis time for older adults compared to children.
  • Data collected included family histories and genetic testing, revealing that a significant proportion of patients had biological relatives also affected by XLH, while most had a confirmed genetic mutation related to the disorder.
View Article and Find Full Text PDF

Introduction: Activation of the focal adhesion kinase (FAK) in podocytes is involved in the pathogenesis of minimal change disease (MCD), but the pathway leading to its activation in this disease is unknown. Here, we tested whether podocyte β1 integrin is the upstream modulator of FAK activation and podocyte injury in experimental models of MCD-like injury.

Methods: We used lipopolysaccharide (LPS) and MCD sera to induce MCD-like changes in vivo and in cultured human podocytes, respectively.

View Article and Find Full Text PDF

Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions Within3, a virtual online platform.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked hypophosphataemia (XLH) is a rare genetic disorder characterized by elevated FGF23 levels, leading to phosphate-wasting and various bone-related issues.
  • Traditional treatments like oral phosphate and vitamin D supplements don't fully address the root causes or all symptoms of the disease.
  • A new study (PASS) is assessing the long-term safety of burosumab, a monoclonal antibody treatment for XLH, using data from a global registry over the next decade.
View Article and Find Full Text PDF

Introduction: Minimal change disease (MCD) is considered a podocyte disorder triggered by unknown circulating factors. Here, we hypothesized that the endothelial cell (EC) is also involved in MCD.

Methods: We studied 45 children with idiopathic nephrotic syndrome (44 had steroid sensitive nephrotic syndrome [SSNS], and 12 had biopsy-proven MCD), 21 adults with MCD, and 38 healthy controls (30 children, 8 adults).

View Article and Find Full Text PDF
Article Synopsis
  • * This variant enhances the receptor's ability to detect guanosine and other molecules, influencing the behavior of B cells and contributing to the development of lupus-like symptoms in mice.
  • * Findings suggest that targeting TLR7 or its downstream partner MyD88 could offer new therapeutic strategies for treating lupus by addressing the aberrant immune responses associated with the disease.
View Article and Find Full Text PDF

Background: Fanconi syndrome (FS) can be of primary or secondary origin. Some cases of FS secondary to the use of sodium valproate (VPA) have been described, mostly in children with severe psychomotor retardation who are fed by feeding device. The objetive of this study was to describe patients treated for this entity in our center, comparing them against the published literature.

View Article and Find Full Text PDF

Minimal change disease (MCD) is the most common type of idiopathic nephrotic syndrome in childhood and represents about 15% cases in adults. It is characterized by massive proteinuria, edema, hypoalbuminemia, and podocyte foot process effacement on electron microscopy. Clinical and experimental studies have shown an association between MCD and immune dysregulation.

View Article and Find Full Text PDF

Introduction: Lupus nephritis is an early manifestation in the development of systemic lupus erythematosus that worsens the morbidity and mortality of these patients.

Objective: To study the form of presentation in patients with lupus nephritis, the clinical and immunological characteristics, and their relationship with renal histology.

Patients And Method: Retrospective study in children under 18 years of age, with lupus nephritis, in follow-up in a third level children's hospital in Madrid, between January 2012 and May 2020.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked hypophosphatemia (XLH) is a rare hereditary disease caused by mutations in the PHEX gene, leading to symptoms like rickets and growth retardation in children, but there is limited data on its clinical spectrum and treatment outcomes.
  • A study of 48 Spanish patients revealed that common findings at diagnosis included bone deformities and significant growth issues, with no difference in severity based on gender and no correlation between gene mutations and clinical manifestations.
  • Conventional treatments, such as phosphate and vitamin D supplementation, were ineffective at improving growth or correcting low phosphate levels over a median follow-up of 7.42 years.
View Article and Find Full Text PDF

Thrombotic thrombocytopaenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterised by microangiopathic haemolytic anaemia, thrombocytopaenia and organ ischaemia. TTP is caused by a severe functional deficiency of ADAMTS13 activity. We describe a 10-year-old girl presenting anaemia and thrombocytopaenia with schistocytes.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease. It is thought that many common variant gene loci of weak effect act additively to predispose to common autoimmune diseases, while the contribution of rare variants remains unclear. Here we describe that rare coding variants in lupus-risk genes are present in most SLE patients and healthy controls.

View Article and Find Full Text PDF

Background & Aims: Iodine deficiency inhibits the normal development of human beings and is the leading cause of preventable mental retardation. Our study aims to update the urinary iodine concentrations and the intake of iodized salt in children in Madrid (Spain).

Methods: A cross-sectional study was designed where 217 children aged 3-14 years old were studied.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked hypophosphatemia (XLH) is a genetic disorder due to PHEX gene mutations that causes various health issues like bone pain, rickets, and dental abscesses, linked to high levels of FGF23.
  • The review explores the role of FGF23 in XLH's complex pathophysiology, investigating different PHEX mutations, animal models, and related diseases of low phosphate levels.
  • It highlights that while elevated FGF23 is a major factor in XLH, other biochemical factors contribute to the disease's symptoms, suggesting areas for future research to improve understanding and treatment strategies.
View Article and Find Full Text PDF

Hemolytic-uremic syndrome (HUS) is defined as the triad of nonimmune hemolytic anemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). The atypical HUS (aHUS) can be considered a subtype of HUS that is rare in childhood and has a worse prognosis. Recent findings have established that the TMA in aHUS are consequences of the disregulation of the complement activation, leading to endotelial damage mediated by the complement terminal pathway.

View Article and Find Full Text PDF

Unlabelled: Mitochondrial diseases (MD) are a heterogeneous group of clinical syndromes characterized by the involvement of different organ systems. They constitute the most prevalent hereditary metabolic disease group.

Objective: To review the importance of the kidney in MD from the nephrologist's perspective within the setting of a pediatric tertiary reference center.

View Article and Find Full Text PDF